Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.

Cardiovasc Diabetol · 2022 · PMC9206286 · PMID 35717169

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)

The proportion of patients with diabetes who initiated insulin treatment during follow-up was lower in the sacubitril/valsartan group than in the valsartan group, but the difference did not reach statistical significance (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62–1.02, P = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.